Motexafin lutetium: Difference between revisions
Appearance
Content deleted Content added
Updating {{chembox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validat... |
Innerstream (talk | contribs) mNo edit summary |
||
(12 intermediate revisions by 11 users not shown) | |||
Line 1: | Line 1: | ||
{{chembox |
{{chembox |
||
| verifiedrevid = |
| verifiedrevid = 455343846 |
||
|ImageFile=Motexafin lutetium. |
| ImageFile=Motexafin lutetium.svg |
||
|ImageSize=200px |
| ImageSize=200px |
||
|IUPACName= |
| IUPACName= |
||
|OtherNames=Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123 |
| OtherNames=Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123 |
||
|Section1={{Chembox Identifiers |
|Section1={{Chembox Identifiers |
||
| CASNo_Ref = {{cascite|correct|??}} |
|||
| |
| CASNo=246252-04-0 |
||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
⚫ | |||
| UNII = 0V38NF6N89 |
|||
⚫ | |||
⚫ | |||
}} |
}} |
||
|Section2={{Chembox Properties |
|Section2={{Chembox Properties |
||
| |
| C=52 | H=72 | Lu=1 | N=5 | O=14 |
||
| |
| Appearance= |
||
| |
| Density= |
||
| |
| MeltingPt= |
||
| |
| BoilingPt= |
||
| |
| Solubility= |
||
}} |
}} |
||
|Section3={{Chembox Hazards |
|Section3={{Chembox Hazards |
||
| |
| MainHazards= |
||
| |
| FlashPt= |
||
| AutoignitionPt = |
|||
| Autoignition= |
|||
}} |
}} |
||
}} |
}} |
||
Line 29: | Line 32: | ||
It is a photosensitiser for use in [[photodynamic therapy]] to treat skin conditions and superficial cancers. |
It is a photosensitiser for use in [[photodynamic therapy]] to treat skin conditions and superficial cancers. |
||
It has also been tested for use in [[photoangioplasty]] (photodynamic treatment of diseased arteries).<ref>[http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-25-2002/0001806282&EDATE= Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease], 2002</ref> |
It has also been tested for use in [[photoangioplasty]] (photodynamic treatment of diseased arteries).<ref>[http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-25-2002/0001806282&EDATE= Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease] {{webarchive|url=https://web.archive.org/web/20110716075826/http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=%2Fwww%2Fstory%2F09-25-2002%2F0001806282&EDATE= |date=2011-07-16 }}, 2002</ref> |
||
It is photoactivated by 732 |
It is photoactivated by 732 nm light which allows greater depth of penetration.<ref>http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T</ref> |
||
==Clinical trials== |
==Clinical trials== |
||
Phase II clinical trials were in progress in 1999.<ref>[http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=141812 Antrin |
Phase II clinical trials were in progress in 1999.<ref>[http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=141812 Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT] {{Webarchive|url=https://archive.today/20120713142335/http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=141812 |date=2012-07-13 }}, 1999</ref> |
||
A phase I trial for [[prostate cancer]] reported in 2009.<ref>{{cite journal | pmid = 18676760 | year = 2008 | last1 = Patel | first1 = H | last2 = Mick | first2 = R | last3 = Finlay | first3 = J | last4 = Zhu | first4 = TC | last5 = Rickter | first5 = E | last6 = Cengel | first6 = KA | last7 = Malkowicz | first7 = SB | last8 = Hahn | first8 = SM | last9 = Busch | first9 = TM | title = Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA | volume = 14 | issue = 15 | pages = 4869–76 | doi = 10.1158/1078-0432.CCR-08-0317 | pmc = 2680073 | journal = Clinical |
A phase I trial for [[prostate cancer]] reported in 2009.<ref>{{cite journal | pmid = 18676760 | year = 2008 | last1 = Patel | first1 = H | last2 = Mick | first2 = R | last3 = Finlay | first3 = J | last4 = Zhu | first4 = TC | last5 = Rickter | first5 = E | last6 = Cengel | first6 = KA | last7 = Malkowicz | first7 = SB | last8 = Hahn | first8 = SM | last9 = Busch | first9 = TM | title = Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA | volume = 14 | issue = 15 | pages = 4869–76 | doi = 10.1158/1078-0432.CCR-08-0317 | pmc = 2680073 | journal = Clinical Cancer Research }}</ref> |
||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
⚫ | |||
[[Category:Tetrapyrroles]] |
[[Category:Tetrapyrroles]] |
||
[[Category:Lutetium |
[[Category:Lutetium complexes]] |
||
⚫ | |||